TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Abnormal Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to Sunitinib Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Numerical Rating Scale Pain Scores (NRS) With Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Numerical Rating Scale Pain Scores (NRS) at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Egg consumption frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT evidence of peculiar patterns in Covid-19 pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of emotion management strategies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dental Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long term efficacy of anti-HBV strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance (kappa score) between actual and estimated physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of restaurants that accomplish the nine compulsory criteria of the Mediterranean Diet certification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dishes per restaurant that have green colour in Traffic light system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dishes offered without food allergens, or vegetarian/vegan options
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grams of macronutrients in the dishes offered in the restaurants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Prematurely Discontinued From the Study Due to Any Reason
Endpoint domain: Adverse events/effects
Primary endpoint: Low anterior resection syndrome score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health Status Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in IOP in the Study Eye at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional Limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient VAS score immediately after the procedure
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Resolution of tympanic effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza-like illness
Endpoint domain: Adverse events/effects
Primary endpoint: Allergic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving SRI-4 Composite Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life: EuroQol Group EQ-5D questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life: European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life: EORTC QLQ-CLL16 (chronic lymphocytic leukaemia) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Long-term HIV care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischaemic heart disease incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Valvular heart disease incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comparability of visual assessment of tau PET images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in YGTSS total tic severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour Levels of Irinotecan and SN-38
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of MRI Scan on Tumour Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best Overall Tumour Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of IPA
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Tumor Response at the Primary Tumor Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total morphine used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough reflex hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: post spinal decrease in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects achieving an erythroid response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse events as a measure of safety
Endpoint domain: Adverse events/effects
Primary endpoint: Metabolic Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental activity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in long term episodic verbal memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Glasgow score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Women With Plasma HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Discontinued Randomized Study Drug Prior to Labor and Delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Women Who Experienced at Least One New Adverse Event of Greater Than or Equal to Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Infants Who Experienced at Least One Adverse Event of Greater Than or Equal to Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Rabies Virus Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ongoing intact pregnancy at 24 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Number of First Primary Episodes of Clostridium Difficile Infection (CDI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Grade II-IV Acute Graft Versus Host Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cmax (Maximum plasma concentration of Tipranavir in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72h (Area Under Plasma Concentration-time curve of Tipranavir from 0-72 hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the Encore Foundation Knee System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise in Mental Illness Questionnaire (EMIQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Internal lymphedema measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: seroconversion rates of antibodies after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of unfavorable hemodynamic state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change on the BRIEF-A Emotional Control Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant Feeding Practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pregnancy Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Delivery Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Newborn Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual renal affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical response rate (PS improvement by ECOG score, analgesic dose reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intracranial aneurysm rupture
Endpoint domain: Mortality/survival
Primary endpoint: Social cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occasion of consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of rheumatological manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Live birth rate after embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: No serious adverse events (SAEs) attributable to ACU
Endpoint domain: Adverse events/effects
Primary endpoint: Change in day time carbon dioxide (CO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events including injection site tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Auclast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of grade >=3 Avastin-related pulmonary hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0-24) for Envarsus XR and IR-Tac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(Max) for Envarsus XR and IR-Tac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(Min) for Envarsus XR and IR-Tac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitrite concentration levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measure of clip ascent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of post-operative complications at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: BOLD response changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERPs changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of loosening of the screw
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of cracking of the screw
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of loosening of the osteochondral fragment
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of cracking of the osteochondral fragment
Endpoint domain: Adverse events/effects
Primary endpoint: time to healing of the osteochondral fragment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in ADHDRS-IV-Parent Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of intrahepatic triglyceride contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute salivary gland toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Positive mutation rate in tumors/IPMN lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: indices of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in red blood cell omega-3 fatty acid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum Total Antioxidant Status (TAS) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Total Oxidant Status (TOS) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Oxidative Stress Index (OSI) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Intubated During Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Died During Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Duration of greater than 50% pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of Medullary 5-HT Neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recording of Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Systemic Filling Pressures (MSFP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Potassium rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of skin delayed type hypersensitivity to metals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Doppler values of portal vein, hepatic vein, renal artery and vein, and splenic vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptance of teriparatide injections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance with teriparatide injections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PSA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential abundances of colonic mucosal and fecal microbial taxa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundances of fecal microbial taxa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of Parkinson's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoglycemia Percentage of Time <70 mg/dL Average by Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Creatinine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in hsCRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interleukin (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of shunt dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lesion Margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood levels of Lipoprotein (a) (Lp(a))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of solicited and unsolicited adverse events post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of solicited and unsolicited adverse events post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Relationship to vaccination of solicited and unsolicited adverse events post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Immunity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of MV-NIS Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of delivering NK cells and ALT-801 in combination with FLAG
Endpoint domain: Adverse events/effects
Primary endpoint: retention rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Millimeters of Bone Loss Surrounding the Implant Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anti-Influenza Serum antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tear Protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity related to AAV2-hFIX administration
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Entrained as Assessed by Urinary aMT6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sCD146 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with sepsis within 28 days after ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: Baseline left cortical excitability modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in left-ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death at day 20
Endpoint domain: Mortality/survival
Primary endpoint: Score of dyspeptic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC0-∞ (Reference Formulation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (Test Formulation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete hematological remission (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: major-amputation-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: outcome of AKI cases presenting to the emergency department
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall adherence to transfusion strategies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: duration of disease remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent prepulse inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Emergency Room Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants Readmitted to Hospital for Respiratory Illness or Dehydration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: threshold for orthostatic intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth trajectories (using BMI, waist circumference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardiac and cerebrovascular events (MACCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: short term survival
Endpoint domain: Mortality/survival
Primary endpoint: Correlation of ablative force with scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Correlation of ablative power with scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Correlation of ablation time on scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Glomerular filtration rate (GFR) at 24 Weeks after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Target registration error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to reach target INR of ≤1.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular Hypertrophy (LVH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of HIV exposed infants receiving EID test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of lower back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of endoscopic diagnosis with manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of chronic kidney disease (CKD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of osteopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes